A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
Clinical trial NCT05061134 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05061134
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-11
- Primary completion
- 2024-04-12
- Enrollment
- 194
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.